Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe
Participants were able to safely and correctly prepare and administer a faricimab 6 mg dose using the PFS in accordance with the instructions for use, under realistic conditions representing the real world. The faricimab 6 mg PFS may therefore offer a more convenient, safe-handling alternative to vial administration.
Authors
- Yannan Tang (ORCID: https://orcid.org/0000-0001-8464-2817)
- Mark Barakat (ORCID: https://orcid.org/0000-0002-1328-6314)
- Liliana P Paris (ORCID: https://orcid.org/0000-0002-9312-9924)
- Henry Kwong
- Petra Schneider (ORCID: https://orcid.org/0000-0001-8561-2679)
- Giovanni Battista Marcon
- Olivia O'Leary
- J. L. GRAFF
Institutions
- Creighton University (US)
- Roche (Switzerland) (CH)
- University of Arizona (US)
- University of Phoenix (US)
- California Retina Consultants (US)
- Macula and Retina Institute (US)
- Retina Macula Institute (US)
- Phoenix College (US)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/opth.s503060
- Citations
- 1
- Primary Topic
- Retinal and Optic Conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Roche
- Biogen
- Alexion Pharmaceuticals
- AbbVie
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Alimera Sciences
- Celltrion
- Apellis Pharmaceuticals
- Coherus Biosciences
- Astellas Pharma
- Genentech
- Allergan